Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, prospective, open-label Phase IV Clinical trial to
evaluate efficacy and safety of interferon alfa-2b therapy combinated with interleukin 2 and
hepatitis B therapeutic vaccine versus interferon alfa-2b alone in chronic hepatitis B
patients with entecavir achieving HBeAg seroclearance. Patients were randomized to one of 3
groups to receive different antiviral treatment.